OPKO HEALTH INC.

Inactive Instrument

Analyst Reco. Opko Health Inc. Nyse

Equities

US68375N1037

End-of-day quote Nyse Other stock markets
- ^USD	-

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	Feb. 28	MT
Barrington Upgrades OPKO Health to Outperform From Market Perform, Price Target is $2	23-06-29	MT
The American consumer comes to the rescue	23-06-28
HC Wainwright Initiates Coverage on OPKO Health With Buy Rating, $3 Price Target	22-12-15	MT
Piper Sandler Adjusts OPKO Health's Price Target to $4 From $5, Reiterates Overweight Rating	22-08-05	MT
Piper Sandler Adjusts OPKO Health's Price Target to $5 From $6, Reiterates Overweight Rating	22-05-10	MT
Barrington Research Downgrades Opko Health Inc to Market Perform From Outperform	22-01-24	MT
OPKO HEALTH : Barrington Adjusts Price Target on Opko Health to $6 From $8 on Lab Unit Revenue Decline, Maintains Outperform Rating	21-07-30	MT
OPKO HEALTH : Ladenburg Thalmann Starts Opko Health at Buy With $7 Price Target	21-06-21	MT
OPKO Health, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018; Provides Revenue Guidance for Third Quarter of 2018; Reaffirms Tax Rate Guidance for the Full Year 2018	18-08-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer